Corvus Pharmaceuticals Inc [NASDAQ: CRVS] closed the trading session at $3.35.
The stocks have a year to date performance of -37.38 percent and weekly performance of -4.83 percent. The stock has been moved at -62.86 percent over the last six months. The stock has performed 18.79 percent around the most recent 30 days and changed -37.85 percent over the most recent 3-months.
If compared to the average trading volume of 760.14K shares, CRVS reached to a volume of 4100077 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Corvus Pharmaceuticals Inc [CRVS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CRVS shares is $15.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CRVS stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Corvus Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 02, 2025. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on August 18, 2023, representing the official price target for Corvus Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $8, while Jefferies analysts kept a Buy rating on CRVS stock.
The Average True Range (ATR) for Corvus Pharmaceuticals Inc is set at 0.25 The Price to Book ratio for the last quarter was 6.98, with the Price to Cash per share for the same quarter was set at 0.76.
CRVS stock trade performance evaluation
Corvus Pharmaceuticals Inc [CRVS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.83. With this latest performance, CRVS shares gained by 18.79% in over the last four-week period, additionally sinking by -62.86% over the last 6 months – not to mention a rise of 75.39% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CRVS stock in for the last two-week period is set at 45.94, with the RSI for the last a single of trading hit 46.17, and the three-weeks RSI is set at 44.55 for Corvus Pharmaceuticals Inc [CRVS]. The present Moving Average for the last 50 days of trading for this stock 3.67, while it was recorded at 3.42 for the last single week of trading, and 5.24 for the last 200 days.
Corvus Pharmaceuticals Inc [CRVS]: An insightful look at the core fundamentals
Corvus Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.54 and a Current Ratio set at 1.54.
Earnings per share (EPS) analysis for Corvus Pharmaceuticals Inc [CRVS] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CRVS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Corvus Pharmaceuticals Inc go to 16.06%.
Corvus Pharmaceuticals Inc [CRVS]: Institutional Ownership
The top three institutional holders of CRVS stocks are: ORBIMED ADVISORS LLC with ownership of 6.94 million shares, which is approximately 11.6289%. SAMLYN CAPITAL, LLC, holding 6.12 million shares of the stock with an approximate value of $$11.14 million in CRVS stocks shares; and SAMLYN CAPITAL, LLC, currently with $$10.86 million in CRVS stock with ownership which is approximately 9.9891%.
